Noguchi Y, Jungbluth A, Richards E C, Old L J
Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11798-801. doi: 10.1073/pnas.93.21.11798.
Interleukin (IL)-12 has strong antitumor activity in transplantable tumor systems in the mouse. The present study was designed to determine whether tumor induction by 3-methylcholanthrene (3-MC), a carcinogenic hydrocarbon, can be inhibited by IL-12. BALB/cBy mice were injected subcutaneously with 25 micrograms or 100 micrograms of 3-MC and treated with 100 ng, 10 ng, or 1 ng of IL-12 for 5 days a week for 18 weeks, with a schedule of 3 weeks on and 1 week off. In mice injected with 25 micrograms of 3-MC, treatment with 100 ng of IL-12 delayed tumor appearance and reduced tumor incidence. Tumor appearance was also delayed in mice injected with 100 micrograms of 3-MC and treated with 100 ng of IL-12, but the final tumor incidence was the same as in non-IL-12-treated mice. In contrast to the characteristically round, hard, well-circumscribed, and protruding tumor induced by 3-MC, a percentage of tumors induced in IL-12-treated mice had atypical characteristics: flat, soft, and invasive. Atypical tumors had a longer latent period and were more frequently seen in mice injected with 100 micrograms of 3-MC and treated with 100 ng of IL-12. Interferon gamma, IL-10, and tumor necrosis factor could be induced throughout the treatment period by IL-12, indicating that repeated injections of IL-12 do not induce a state of tachyphylaxis. High production of interferon gamma by CD8 T cells and a TH2-->TH1 or TH0 shift in the cytokine secretion profile of CD4 T cells were also seen in the IL-12-treated mice. IL-12 provides a powerful new way to explore the defensive role of the immune system in tumorigenesis.
白细胞介素(IL)-12在小鼠可移植肿瘤系统中具有强大的抗肿瘤活性。本研究旨在确定致癌烃3-甲基胆蒽(3-MC)诱导的肿瘤是否能被IL-12抑制。将25微克或100微克的3-MC皮下注射到BALB/cBy小鼠体内,并分别用100纳克、10纳克或1纳克的IL-12进行治疗,每周治疗5天,持续18周,治疗方案为3周治疗、1周休息。在注射25微克3-MC的小鼠中,用100纳克IL-12治疗可延迟肿瘤出现并降低肿瘤发生率。在注射100微克3-MC并用100纳克IL-12治疗的小鼠中,肿瘤出现也延迟了,但最终肿瘤发生率与未用IL-12治疗的小鼠相同。与3-MC诱导的典型圆形、坚硬、边界清晰且突出的肿瘤不同,在接受IL-12治疗的小鼠中诱导产生的一定比例的肿瘤具有非典型特征:扁平、柔软且具有侵袭性。非典型肿瘤的潜伏期更长,在注射100微克3-MC并用100纳克IL-12治疗的小鼠中更常见。在整个治疗期间,IL-12均可诱导γ干扰素、IL-10和肿瘤坏死因子产生,这表明重复注射IL-12不会诱导速发耐受状态。在接受IL-12治疗的小鼠中还观察到CD8 T细胞产生大量γ干扰素,以及CD4 T细胞细胞因子分泌谱从TH2向TH1或TH0转变。IL-12为探索免疫系统在肿瘤发生中的防御作用提供了一种强有力的新方法。